{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/aphthous-ulcer/prescribing-information/benzydamine-hydrochloride/","result":{"pageContext":{"chapter":{"id":"71959a98-dede-5b80-8412-62b92c7172f4","slug":"benzydamine-hydrochloride","fullItemName":"Benzydamine hydrochloride","depth":2,"htmlHeader":"<!-- begin field 83c26923-3bac-4977-87b0-a75800d85467 --><h2>Benzydamine hydrochloride</h2><!-- end field 83c26923-3bac-4977-87b0-a75800d85467 -->","summary":"","htmlStringContent":"<!-- begin item 4139f236-1b90-40ad-8aa3-a75800d8519d --><!-- end item 4139f236-1b90-40ad-8aa3-a75800d8519d -->","topic":{"id":"0d0cd284-920f-5a4d-af22-e60387034bd3","topicId":"a8bbf75a-0ba0-4cf4-aa6d-c04c197470ee","topicName":"Aphthous ulcer","slug":"aphthous-ulcer","lastRevised":"Last revised in April 2017","chapters":[{"id":"c5681466-1d53-592e-a6f3-ef09c26590f6","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"57a52c12-af9a-58cc-8652-e510af025137","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"78568ea4-ac58-5f85-b614-4f6349e25cc6","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"4cc5e97a-0fae-51bc-808e-e6d06f3d1bf0","slug":"changes","fullItemName":"Changes"},{"id":"133d9798-49cd-5211-bf2a-bac0f674f0a1","slug":"update","fullItemName":"Update"}]},{"id":"c8dc5503-619d-58f3-86ff-d0321f0ceabb","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"53b4a0fd-899b-547c-8522-7ca2034e0739","slug":"goals","fullItemName":"Goals"},{"id":"a531a007-31cf-5b5c-9120-0c2e4d33757d","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2ec63555-d923-5190-a236-662ab9fd12e6","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f3d6c286-8aac-5529-87e8-073f78d63ccb","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"edb5e193-54cf-5552-83b9-38aa7f31e0b7","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0ec0b271-e6c7-58fe-8588-6fede72a6528","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"acbcb9eb-b6e3-5544-a64c-bbf327bf7196","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e8fbc455-fba9-5a7b-8488-ab5ba5cb7f23","slug":"definition","fullItemName":"Definition"},{"id":"5d4f91c1-0b7e-5b2e-a7d9-3cb851a4724f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"8f142ca7-f145-5707-96bd-2e872abec04c","slug":"causes","fullItemName":"Causes"},{"id":"0fe4abe0-ac8a-596c-89fb-6308469ffccc","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"6b590897-ea1c-5f81-a10f-5231856a4218","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"85e6ad3b-53b9-569a-85d9-0d89cade7baf","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"9e8b8716-00db-5198-848b-1499dbe6ebfc","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"c2255f6f-94df-5102-b8f5-b0ce847ccd0b","fullItemName":"Management","slug":"management","subChapters":[{"id":"99359365-5779-5dc9-a70c-06c437fa4bec","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"043b58c8-35cb-5bde-947d-ad6745ce6442","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"fdc1200c-28a7-549e-badb-49b57809d89d","slug":"beclometasone-dipropionate","fullItemName":"Beclometasone dipropionate"},{"id":"8a9bea80-2abd-5c4c-8f3f-1808d885ad28","slug":"betamethasone-soluble-tablets","fullItemName":"Betamethasone soluble tablets"},{"id":"6b4324bf-8c13-548c-aa78-c03fe2d7ae38","slug":"hydocortisone-oromucosal-tablets","fullItemName":"Hydocortisone oromucosal tablets"},{"id":"4a2cbdae-edfd-5ee4-a8c6-fb2bc2ee37d6","slug":"oral-prednisolone","fullItemName":"Oral prednisolone"},{"id":"71959a98-dede-5b80-8412-62b92c7172f4","slug":"benzydamine-hydrochloride","fullItemName":"Benzydamine hydrochloride"},{"id":"0973c3a1-9b56-5a4e-8be8-2bdc1a2086e3","slug":"chlorhexidine","fullItemName":"Chlorhexidine"},{"id":"d2706d4a-55cb-558d-b051-48b760c89259","slug":"doxycycline-rinses","fullItemName":"Doxycycline rinses"},{"id":"4113f257-00a4-5ae5-bf7e-6779f04fc835","slug":"lidocaine-hydrochloride","fullItemName":"Lidocaine hydrochloride"},{"id":"1856d033-bfca-5001-b8ed-bb55f0981a0e","slug":"cyanocobalamin","fullItemName":"Cyanocobalamin"}]},{"id":"3941ff63-446e-556a-87b3-af80dbd8dba9","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"94c5ca61-9355-514f-ba99-256e7c8d2913","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a71bf9fe-164d-54fb-82e2-2aa5ceec590b","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a24bf4ae-506c-51aa-84b7-73436ec0ac43","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7f107881-b247-54f5-850f-c340b8187b07","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"41016397-9e4e-5617-9713-825e45d3ae1c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6e858140-2320-5176-9cd5-22bec3ae597a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"fb71f4be-d743-5e4f-81a8-da0a88971d9f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"043b58c8-35cb-5bde-947d-ad6745ce6442","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"8763caa7-97fb-5da5-af42-956644722582","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field f04e87e6-b391-4c8c-b801-a75800d9e705 --><h3>Dose</h3><!-- end field f04e87e6-b391-4c8c-b801-a75800d9e705 -->","summary":"","htmlStringContent":"<!-- begin item f1e58ce6-e1a1-4778-97e6-a75800d954b5 --><!-- begin field 030155cd-2117-458f-9292-a75800d9e705 --><p><strong>Mouthwash:</strong>  </p><ul><li>Children aged 13 years and over, and adults — rinse 15 mL every 1.5 to 3 hours as required. Dilute with an equal volume of water if stinging occurs.</li></ul><p><strong>Oromucosal spray: </strong></p><ul><li>Children 1 month to 5 years — 1 spray to the affected area every 1.5 to 3 hours (max. per dose, 4 sprays every 1.5 to 3 hours), one spray per 4 kg body weight.</li><li>Children 6 to 11 years — 4 sprays to the affected area every 1.5 to 3 hours.</li><li>Children 12 years and over, and adults — 4 to 8 sprays to the affected area every 1.5 to 3 hours.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/aphthous-ulcer/references/\">BNF 73, 2017</a>]</p><!-- end field 030155cd-2117-458f-9292-a75800d9e705 --><!-- end item f1e58ce6-e1a1-4778-97e6-a75800d954b5 -->","subChapters":[]},{"id":"4b31ec6c-00c5-54bd-9690-271727c54d4d","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 7ba4dd9d-e807-4f25-bfeb-a75800d8eaa7 --><h3>Adverse effects</h3><!-- end field 7ba4dd9d-e807-4f25-bfeb-a75800d8eaa7 -->","summary":"","htmlStringContent":"<!-- begin item 21c8db98-7d41-4625-9e19-a75800d8e5ff --><!-- begin field 7e5fcf10-0795-4503-9d53-a75800d8eaa7 --><ul><li><strong>The most common adverse effect of benzydamine hydrochloride is oral numbness or stinging.</strong></li><li><strong>Other adverse effects of benzydamine hydrochloride include:</strong><ul><li>Hypersensitivity reactions which may be associated with pruritus, urticaria, photosensitivity reaction, and rash</li><li>Laryngospasm or bronchospasm.</li><li>Angioedema.</li><li>Anaphylactic reactions.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/aphthous-ulcer/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/aphthous-ulcer/references/\">ABPI, 2017</a>]</p><!-- end field 7e5fcf10-0795-4503-9d53-a75800d8eaa7 --><!-- end item 21c8db98-7d41-4625-9e19-a75800d8e5ff -->","subChapters":[]},{"id":"91fe3419-8dc4-57a4-a44d-36b2b6c5cc31","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 970bc9ab-dc64-4697-be60-a75800d8c663 --><h3>Contraindications and cautions</h3><!-- end field 970bc9ab-dc64-4697-be60-a75800d8c663 -->","summary":"","htmlStringContent":"<!-- begin item 230148ec-c794-42cf-bca5-a75800d8c0f8 --><!-- begin field 452e9d11-5175-46fb-a461-a75800d8c663 --><p><strong>Do not prescribe benzydamine hydrochoride to:</strong></p><ul><li>Pregnant women.</li><li>People with known hypersensitivity to any of the ingredients.</li></ul><p><strong>Prescribe benzydamine hydrochoride with caution to:</strong></p><ul><li>Breastfeeding women</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/aphthous-ulcer/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/aphthous-ulcer/references/\">ABPI, 2017</a>]</p><!-- end field 452e9d11-5175-46fb-a461-a75800d8c663 --><!-- end item 230148ec-c794-42cf-bca5-a75800d8c0f8 -->","subChapters":[]},{"id":"df3f2e4e-d908-5575-9163-a855ff31ee88","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field a95f1a6c-9400-4b9c-ab50-a75800d9349b --><h3>Drug interactions</h3><!-- end field a95f1a6c-9400-4b9c-ab50-a75800d9349b -->","summary":"","htmlStringContent":"<!-- begin item b52f3647-8ede-48bd-b39b-a75800d931f0 --><!-- begin field 2566ca40-3714-4b9a-8c93-a75800d9349b --><p>There are no known drug interactions for topical benzydamine hydrochloride.</p><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/aphthous-ulcer/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/aphthous-ulcer/references/\">ABPI, 2017</a>]</p><!-- end field 2566ca40-3714-4b9a-8c93-a75800d9349b --><!-- end item b52f3647-8ede-48bd-b39b-a75800d931f0 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}